regulatorisk
Årsredovisningen kan laddas ner från hemsidan eller beställas från Qlife, info@egoo.health.
För ytterligare information vänligen kontakta:
Thomas Warthoe, VD Qlife Holding
Epost: tw@egoo.health...
regulatorisk
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
icke
regulatorisk
Qlife is a first mover in the growing market for at-home, lab-grade biomarker testing. The company’s strategic roadmap focuses on the following areas:
Hospital-at-Home - China market
Egoo Phe...
icke
regulatorisk
The clinical trial will run for six months in the UK, after which the dossier will be submitted to the relevant UK authorities. As self-testing by non-professional users represents the highest...
regulatorisk
Val och arvodering av styrelse
Stämman beslutade att omvälja styrelseledamöterna Lars Staal Wegner och Mikael Persson samt att välja Flemming Pedersen, Jørgen Drejer och Jacob Glenting som...
regulatorisk
The rights issue that was announced on 29 January 2025 (the “Rights Issue”) in Qlife Holding AB (publ) (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office (...
regulatorisk
Qlife Holding AB (publ) (“Qlife” or the “Company”) has completed the issue of shares with preferential rights for the Company's shareholders that was resolved by the Board of Directors on 29 ...
icke
regulatorisk
With approximately 91 percent subscription in the rights issue and a secured credit facility, Qlife has ensured financing for at least the next 12 months. The company is now able to solely focus on...
regulatorisk
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
regulatorisk
On 29 January 2025, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of approximately SEK 11.8 million (the “Rights Issue”). The subscription period of the Rights Issue ended on...
regulatorisk
Tuesday, 25 February 2025, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of approximately SEK 11.8 million (the “Rights Issue”). Please note...
icke
regulatorisk
On 28 January 2025, Qlife signed a Letter of Intent (LOI) with a top-20 global pharmaceutical company to explore potential commercial collaborations. Among the key criteria outlined in the LOI was...
icke
regulatorisk
The newly introduced Women’s Health product covers key aspects of fertility, menopause, thyroid disease and Vitamin D, enabling users to track and understand hormonal changes that impact their...
regulatorisk
The newly added biomarkers for Thyroid Disease and Vitamin D will be launched on the recently announced CE-IVD-marked platform, developed in collaboration with Hipro Biotechnology. With the addition...
regulatorisk
The non-binding intention from the Board of Directors and management amounts to approximately 1.2 MSEK. In addition, Lars Bangsgaard is also participating in the top-down-guarantee that was...
regulatorisk
Today, 11 February 2025, is the first day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) issue of a maximum of 5,883,817 shares with preferential rights for existing...
regulatorisk
The Board of Directors of Qlife Holding AB (“Qlife” or the “Company”) has, in connection with the Company's upcoming rights issue that was announced on 29 January 2025 (the “Rights Issue”), prepared...
regulatorisk
Financial summary – fourth quarter 2024
Revenue in the period amounted to kSEK 50 (30).
EBITDA for the period amounted to kSEK –7,721 (-86,903), and net loss kSEK – 7,106 (-111,545)....
regulatorisk
The sanction relates to an incident in February 2023 when Thomas Warthoe forwarded an email with details related to a rights issue. The e-mail was forwarded to Peter Warthoe, CSO of the company and...
regulatorisk
Today, the Board of Directors in Qlife Holding AB (“Qlife” or the “Company”) has, with the authorisation granted from the annual general meeting held on 26 June 2024, resolved to carry out an issue...
regulatorisk
Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will...
regulatorisk
Qlife and Hipro Biotechnology have joined forces to introduce a jointly developed, CE-IVD-marked platform to the market. This new solution combines the best of Hipro’s technology with Egoo Health’s...
icke
regulatorisk
The company has shifted its focus from research and development to becoming a sales-driven organization, emphasizing the distribution of its high-quality Egoo Health product platform in the rapidly...
icke
regulatorisk
Since the summer, Qlife has been working diligently in close collaboration with its partner, Hipro Biotechnology, in China. The company is pleased to share the following updates:
Excellent...
regulatorisk
The exercise period for warrants of series TO 5 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue of units in February 2024 (the "Rights Issue") begins...
regulatorisk
Qlife har informerats om att Stefan Kylebäck kommer att efterträdas av Mattias Olofson som således kommer blir ny huvudansvarig revisor för Qlife. Bytet sker omgående.
För ytterligare...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTH KOREA...
regulatorisk
Beslut om huruvida bolaget ska träda i likvidation eller driva verksamheten vidare
Det konstaterades att den andra kontrollbalansräkningen utvisar att bolagets eget kapital är helt återställt. Med...
regulatorisk
Financial summary – third quarter 2024
Revenue in the period amounted to kSEK 0 (45).
EBITDA for the period amounted to kSEK –27,151 (-6,660), and net loss kSEK – 28,087 (-8,926).
The total...
regulatorisk
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
regulatorisk
On 29 August 2024, Qlife announced its intention to change the Company’s name to Egoo Health AB as part of a broader rebranding initiative. However, the Swedish Companies Registration Office has...
icke
regulatorisk
An at-home PHE test will significantly improve the quality of life for people with Phenylketonuria. Qlife's regulatory strategy involves releasing the product as a CE-RUO test, backed by sufficient...
regulatorisk
An at-home PHE test will significantly improve the quality of life for people with Phenylketonuria. Qlife's regulatory strategy involves releasing the product as a CE-RUO test, backed by sufficient...
regulatorisk
Peter Warthoe is one of the co-founders of Qlife but decided a few years ago to step out of the management role to focus more on his scientific projects. Given the company’s new lean structure and...
regulatorisk
On 21 March 2024, the Company presented a balance sheet for liquidation purposes, showing that the equity was less than half of the registered share capital. On 28 March 2024, Qlife announced that...
icke
regulatorisk
The Company reports that, in collaboration with its partner Hipro, progress has been made on the four key objectives set for their partnership. The integration and validation of Hipro biochemistry...
icke
regulatorisk
As outlined in the press release dated 29 August 2024, Qlife has successfully executed directed issues of shares and warrants pursuant to the authority granted by the annual general meeting 2024....
regulatorisk
Qlife Holding AB (publ) (“Qlife” or the “Company”) announces the acquisition of the assets of the Company's subsidiary Qlife ApS in bankruptcy, including goodwill and...
regulatorisk
Financial summary – second quarter 2024
Revenue in the period amounted to kSEK 39 (46).
EBITDA for the period amounted to kSEK –8,002 (-16,287), and net loss kSEK –12,979 (-22,703).
The total...
regulatorisk
Årsstämman i Qlife beslutade den 26 juni 2024 om sammanläggning av aktier 1:2000, innebärande att 2000 befintliga aktier läggs samman till 1 aktie. Styrelsen i Qlife fastställde avstämningsdagen för...
regulatorisk
Today, the reconstructor, has concluded that there is no viable path to secure financing for Qlife’s subsidiary, Qlife ApS. Consequently, the board of directors has decided to declare...
regulatorisk
Sammanläggning av aktier
Årsstämman beslutade den 26 juni 2024 om sammanläggning av aktier varigenom tvåtusen (2 000) befintliga aktier läggs samman till en (1) aktie. För att möjliggöra...
icke
regulatorisk
For a couple of weeks during June Qlife was invited to participate Emory’s Metabolic Camp and run a research trial with the aim of making a comparison study of blood data on Egoo compared to data...
regulatorisk
Qlife Holding AB höll den 26 juni 2024 årsstämma varvid i huvudsak följande beslut fattades.
Fastställande av räkenskaper samt resultatdisposition
Årsstämman beslutade att fastställa resultat- och...
regulatorisk
On 13 March 2023, Qlife Holding AB (“Qlife” or the “Company”) announced that Aidian Oy had initiated arbitration proceedings against Qlife’s wholly owned subsidiary Qlife ApS regarding payment of...
regulatorisk
Qlife Holding AB (“Qlife” or the “Company”) and Atlas Special Opportunities, LLC (“Atlas”), have entered into a non-binding term sheet on 13 May 2024. According to the term sheet, Atlas will fund the...
regulatorisk
Terms for warrants series TO 4 in brief:
The exercise price is SEK 0.02 per share.
The exercise period runs from 7 – 21 June 2024.
Each warrant entitles the holder to subscribe for one (1) share...
regulatorisk
Årsredovisningen kan laddas ner från hemsidan eller beställas från Qlife, info@egoo.health.
För ytterligare information vänligen kontakta:
Thomas Warthoe, VD Qlife Holding
Epost: tw@egoo.health...
regulatorisk
Since last year, Qlife has worked diligently towards transferring the Egoo Health platform to Hipro in China to setup pilot production of consumables, validate performance with Hipro reagents, and...
regulatorisk
Financial summary – first quarter 2024
Revenue in the period amounted to kSEK 0 (123). No revenue of Egoo.Health devices and capsules for the device.
EBITDA for the period amounted to kSEK –11,...
regulatorisk
Rätt att delta och anmälan
Den som önskar delta i stämman ska:
dels vara upptagen som aktieägare i den av Euroclear Sweden AB framställda aktieboken avseende förhållanden på avstämningsdagen som...
regulatorisk
On 3 August 2024, the board of directors of the Company resolved on a directed issue of convertible debentures, with a total owed amount before interest of SEK 7,745,058 (including the set-up fee)....
regulatorisk
Resolution on whether the company shall enter into liquidation or continue its operations
The extraordinary general meeting resolved in accordance with the primary proposal from the board of...
regulatorisk
“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time...
regulatorisk
“Qlife is following our operational plans, but since we have a called for an extraordinary general meeting later this month to resolve on the company’s balance sheet, we have chosen at the same time...
regulatorisk
The rights issue of units that was announced on 12 December 2023 (the “Rights Issue”) in Qlife Holding AB (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office...
icke
regulatorisk
It has been mentioned in the media that Qlife is no longer focused on the EU and other markets. However, as communicated previously, Qlife is focused on finalizing regulatory work in China and roll-...
regulatorisk
Qlife is pleased to announce that it has signed a Letter of Intent (LOI) with leading South Korean company Precision Biosensor, to introduce Egoo Health to the South Korean market. Qlife anticipates...
regulatorisk
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The shareholders of Qlife Holding AB...
icke
regulatorisk
Qlife has today called for an EGM because it is obliged to do so when the company has written down half of its equity as previously communicated in connection with the company’s year-end report for...
regulatorisk
As communicated in the Company’s year-end report for the financial year 2023, the board of directors of Qlife has, in accordance with Chapter 25, Section 13 of the Swedish Companies Act, prepared a...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke
regulatorisk
The key feature of the innovation is the ability to perform analysis in a microenvironment with fixed alignment, so no variability is seen between analysis and readout.
“This core patent protects...
icke
regulatorisk
The collaboration consists of four major parts:
Integration of reagents
Regulatory approval in China
Distribution and sales in China
Production of Egoo in China
Integration of reagents
The...
icke
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
Financial summary – fourth quarter 2023
Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is...
regulatorisk
Financial summary – fourth quarter 2023
Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is solely from...
regulatorisk
The postponement is due to administrative reasons.
This information was submitted for publication, through the agency of the contact person set out above, on 2024-02-04 21:53 CET.
regulatorisk
Resolution on (A) amendment of the Articles of Association; and (B) reduction of the share capital without redemption of shares
The extraordinary general meeting resolved in accordance with the...
regulatorisk
Right to participate and notification
Shareholders wishing to participate in the meeting must:
partly be listed in the company’s share register kept by Euroclear Sweden AB as of Monday 8 January...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke
regulatorisk
Qlife has on Monday 4th of December entered into a final collaboration agreement with Hipro Biotechnology. The parties will from now on work diligently towards achieving market clearance for Egoo...
icke
regulatorisk
The agreement in brief
The agreement consists of four major parts:
Integration of reagents
Regulatory approval from the China Food and Drug Administration for Egoo Health
Distribution and sales...
regulatorisk
Peter Thorsen is a Certified Public Accountant (CPA) with an impressive background in finance, having previously served in key roles at prominent organizations such as EY, DSV A/S, Domea, Widex A/S,...
regulatorisk
Financial summary – third quarter 2023
Revenue in the period amounted to kSEK 45 (1,967). Revenue includes sales of Egoo.
Health devices and capsules for the device. Revenue in Q3 is solely...
regulatorisk
In total, Qlife issued 622,348,940 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 3. One (1) warrant entitled the right to subscribe for one (1) new share...
regulatorisk
The technology and overall strategy
Qlife has invested more than SEK 300 million in the development of Egoo Health, a unique biomarker self-testing system for measuring and monitoring blood data...
regulatorisk
Terms for warrants series TO 3 in brief:
The exercise price is SEK 0.11 per share.
The exercise period runs from 11 – 29 September 2023.
Each warrant entitles the holder to...
regulatorisk
Financial summary – second quarter 2023
In Q2 2023 QLife has completed restructuring of its operation by reducing the number of employees and terminating a long term lease for...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke
regulatorisk
At AACC/Clinical Lab Expo, the open system Egoo Innovate was launched and Qlife demonstrated how Egoo Innovate can be a game-changer in promoting faster and targeted implementation of critical...
icke
regulatorisk
The open system provides the opportunity of innovating and implementing proprietary biomarker assay projects on to the at-home diagnostic system. Now, researchers can join the quest to broaden access...
regulatorisk
In total, Qlife issued 2,884,980 units in the Rights Issue, each consisting of one (1) share and one (1) warrant series TO 2. One (1) warrant entitled the right to subscribe for 1.08 new shares in...
icke
regulatorisk
Since the start of 2023, Qlife has continuously scaled down on costs, workforce and operates mainly by outsourcing. The termination of the lease is part of Qlife’s new operation model to implement...
icke
regulatorisk
“Since the IPO in March 2020 Qlife has achieved a lot of encouraging goals”, says CEO Thomas Warthoe. “We have continuously listened to the market to adjust our offers and have now concluded that we...
regulatorisk
Terms for warrants series TO 2 in brief:
The exercise price has been set to SEK 0.21 per share. The exercise price has been defined as seventy (70) per cent of the volume-weighted average price...
regulatorisk
The rights issue of units that was announced on 16 February 2023 (the “Rights Issue”) in Qlife Holding AB (“Qlife” or the “Company”) has been registered with the Swedish Companies Registration Office...
regulatorisk
Financial summary – first quarter 2023
Revenue in the period amounted to kSEK 123 (10,905). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test...
regulatorisk
On 4 May 2023, the annual general meeting was held in Qlife Holding AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority.
Resolution on...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
Subscription and allotment
The subscription summary shows that 122,853,750 units, corresponding to approximately 21.3 percent of the Rights Issue, were subscribed for by exercise of unit rights. In...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
The full report is available in English at the following url.:
https://qlifeholding.com/en/investors/finansiella-rapporter
Qlife has changed to English as the sole language for market...
regulatorisk
Rätt att delta och anmälan
Aktieägare som önskar delta i årsstämman ska:
dels vara införd i den av Euroclear Sweden AB förda aktieboken tisdagen den 25...
regulatorisk
Qlife’s Nomination Committee proposes that the Annual General Meeting elects Lars Bangsgaard as new Chairman of the Board, Lars Wegner as new Board member and re-election of Mette-Marie Harild,...
regulatorisk
Beslut om ändring av bolagsordningen
Den extra bolagsstämman beslutade i enlighet med styrelsens förslag att ändra bolagsordningen så att gränserna för...
icke
regulatorisk
In 2020, Qlife entered into a cooperation with the Finnish company Aidian Oy. Several agreements between the parties were concluded in 2020 and 2021, according to which Qlife undertook to purchase...
regulatorisk
Rätt att delta och anmälan
Aktieägare som önskar delta i stämman ska:
dels vara införd i den av Euroclear Sweden AB förda aktieboken torsdagen den 16 mars 2023;
dels anmäla sig till bolaget...
regulatorisk
Summary of the Rights Issue
The Rights Issue is proposed to be carried out on the following main terms:
The Rights Issue comprises a maximum of 576,813,400 units, corresponding to a maximum of...
regulatorisk
Financial summary – fourth quarter 2022
Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test...
regulatorisk
Financial summary – fourth quarter 2022
Revenue in the period amounted to kSEK 1,097 (12,084). Revenue includes sales of Egoo.Health devices and capsules for the device. COVID test...
icke
regulatorisk
“With this launch, Qlife really can start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health-conscious audience and for home use”, says...
icke
regulatorisk
With the launch of our CRP capsule, Qlife will start delivering on our vision of bringing lifestyle biomarker testing with quantitative precise data to a wider health conscious audience and for home...
icke
regulatorisk
Qlife has been able to develop a small, freeze-dried bead that consist of the CRP reagents used in the Egoo CRP Capsule. Instantly frozen reagents which then are freeze-dried into spherical beads are...
regulatorisk
Financial summary – third quarter 2022
Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales ofEgoo.Health devices and capsules for the device. Continued...
regulatorisk
Financial summary – third quarter 2022
Revenue in the period amounted to kSEK 1,967 (5,871). Revenue includes sales ofEgoo.Health devices and capsules for the device. Continued...
icke
regulatorisk
On November 24th at 14:20 Qlife's CFO, Kasper Boel Rousøe will presentthe latest developments in the company at Redeye. We will do an in-depth interview, called InFocus. The interview will...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
regulatorisk
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH...
icke
regulatorisk
This is the largest biohacker event in the world and gathers people, companies, and organizations across the medical, health, and wellbeing sector, providing an optimal platform for networking,...
icke
regulatorisk
During the past year, Qlife has been transitioning and transforming to a post-covid reality. The current cost reductions are related to a significantly reduced demand for covid-tests and primarily...
icke
regulatorisk
September 26 at Stora Aktiedagen in Lund
Venue: Elite Hotel Ideon
Time: 08.30-09.00
The presentation will be held in English and the event is open to the public, as well as live-streamed and...
icke
regulatorisk
Qlife updates vision and websites – reinforced emphasis on making Egoo Health available for home use
Qlife was founded based on the idea that Egoo Health could help people lead a better life by using the diagnostics self-testing platform Egoo Health. Today, the short-term focus is on completing...
icke
regulatorisk
Från den 1 april 2022 publicerar Qlife inte längre pressmeddelanden på svenska. Alla nyheter finns här (https://qlifeholding.com/en/investors/news).
icke
regulatorisk
Som studieupplägg använde Hvidovre Hospitals best practice för covid-19-testning (RT-qPCR) som jämförelsemetod. Därmed avviker testutförande från den för Egoo.Healths avsedda användningen och...
icke
regulatorisk
"Vi är överraskade att resultatet från den danska utvärderingen skiljer sig från en annan vetenskaplig och publicerad studie omfattande mer än 1000 prover som bland annat genomförts tillsammans...
regulatorisk
FJÄRDE KVARTALET 1 OKTOBER - 31 DECEMBER 2021
Periodens intäkter uppgick till 12 084 (9 122) KSEK. Försäljning avser Egoo.Health enheter och COVID-19 test kapslar.
EBITDA för perioden uppgick...
regulatorisk
Qlife har tecknat ett avtal med FIND, the global alliance for diagnostics, om en finansiering på 3,45 MUSD för ett 12-månaders projekt med målet att utveckla ett nytt två-i-ett-test för upptäckt av...
regulatorisk
Kasper Rousøe har mer än 20 års erfarenhet från ledande roller inom det finansiella området, senast från Phase One A/S. Han har tidigare varit CFO och finansdirektör i Bauer Media Group, Mono...
regulatorisk
TREDJE KVRATALET 1 JULI - 30 SEPTEMBER 2021
Periodens intäkter uppgick till 5 871 (5 062) KSEK och avser försäljning av COVID-19 tester från servicecenter, samt Egoo.Health enheter och ...
icke
regulatorisk
Idag får de flesta sin diagnos genom så kallad kvantitativ polymeraskedjereaktion (qRT-PCR) som utförs i specialiserade laboratorier. Det innebär att det ofta tar mer än 24...
icke
regulatorisk
I enlighet med beslutet vid Qlife Holding årsstämma 2021 har bolagets styrelseordförande sammankallat en valberedning för att förbereda förslag inför bolagets årsstämma 2022. Valberedningen består av...
icke
regulatorisk
Onsdagen den 1 december på Stora Aktiedagen i Stockholm
Kl 12.00-12.30
Torsdagen den 2 december på Västra Hamnen i Malmö
Kl. TBD
Investerare, analytiker och media behöver anmäla sig till...
regulatorisk
”Det har varit en fantastisk resa som jag är stolt över att ha varit med på. Min expertis är framförallt att bistå bolag i uppstartsfas, och det är Qlife verkligen inte längre, och därför är det rätt...
regulatorisk
ANDRA KVRATALET 1 APRIL - 30 JUNI 2021
Periodens intäkter uppgick till 10 482 (6 181) KSEK och avser försäljning av COVID-19 tester från servicecenter, samt Egoo.Health enheter och kapslar....
icke
regulatorisk
De flesta får idag sin diagnos genom så kallad kvantitativ polymeraskedjereaktion (qRT-PCR) som utförs i specialiserade laboratorier. Det innebär att det ofta tar mer än 24 timmar från testtillfälle...
icke
regulatorisk
I samband med EM i fotboll i Köpenhamn de närmaste veckorna utökar Qlife sin testkapacitet för Covid-19 för att ge fler tillgång till RT-PCR-testning med garanterad respons inom 8 timmar (svar samma...
icke
regulatorisk
Uppdelningen innebär att Thomas Warthoes, Peter Warthoes och Lars Bangsgaards respektive bolag har förvärvat 1 201 200 aktier var av PKV Consult IVS, och Ebbe Finding är nu ensam ägare av...
regulatorisk
Utnyttjandeperioden för teckningsoptionerna av serie TO 1 ägde rum från och med den 3 maj 2021 till och med den 31 maj 2021. Teckningskursen per aktie för utnyttjande av teckningsoptionerna av serie...
regulatorisk
Vid årsstämman den 5 maj 2021 beslutades om ett incitamentsprogramprogram riktat till tre nya styrelseledamöter i bolaget. Optionsvillkoren baseras på en marknadsmässig värdering enligt...
icke
regulatorisk
Innehavare av teckningsoptioner äger rätt att för varje två (2) ägda teckningsoption av serie TO1 teckna en (1) ny aktie i Qlife till ett pris om 17,50 SEK per aktie. Antalet teckningsoptioner av...
regulatorisk
Beslut om fastställande av räkenskaper samt resultatdisposition
Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade...
regulatorisk
FÖRSTA KVARTALET 1 JANUARI - 31 MARS 2021
Periodens intäkter uppgick till 11 176 (385) KSEK och avser försäljning av COVID-19 tester från servicecenter och Egoo.Health enheter och kapslar för...
regulatorisk
Nyttjandeperioden pågår från och med den 3 maj 2021 fram till och med den 31 maj 2021. Två (2) teckningsoptioner berättigar till teckning av en (1) ny aktie i Bolaget...
regulatorisk
EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SINGAPORE, SYDAFRIKA...
icke
regulatorisk
Qlife bjuder in investerare, analytiker och media till en presentation av kvartalsrapporten där CEO Thomas Warthoe ger sina kommentarer på rapporten.
Rapporten släpps klockan 08:00 och kommer att...
regulatorisk
Qlife har varit en del av ett utvecklingsprogram vid onkologiavdelningen på Herlev Hospital sedan 2018, avsett att validera monitorering i hemmet av njurcancerpatienter. Projektet har försenats flera...
regulatorisk
Avtalet omfattar en rad europeiska länder, inklusive Sverige, Norge, Finland, Tyskland, Nederländerna, Belgien, Luxemburg, Österrike, Schweiz, Polen, Tjeckien, Ungern, Slovakien, Rumänien, Slovenien...
regulatorisk
Årsredovisningen kan laddas ned från hemsidan eller beställas från bolaget, info@egoo.health.Informationen är sådan som Qlife Holding AB är skyldigt att offentliggöra enligt lag (2007:528) om...
regulatorisk
Aktieägarna i Qlife Holding AB, org. nr 559224-8040 (”Qlife”), kallas till årsstämma onsdagen den 5 maj 2021.
Mot bakgrund av den pågående covid-19-pandemin och i syfte att minska risken för...
regulatorisk
Mot bakgrund av den pågående covid-19-pandemin och i syfte att minska risken för smittspridning har styrelsen beslutat att årsstämman ska hållas enbart genom förhandsröstning (poströstning) med stöd...
regulatorisk
Qlife’s valberedning föreslår att årsstämman väljer Mette-Marie Harild, Ulrik Harrysson och Mikael Persson till nya styrelseledamöter.
Mette-Marie Harild, född 1958, har lång erfarenhet av att leda...
regulatorisk
FJÄRDE KVARTALET 1 OKTOBER - 31 DECEMBER 2020
Periodens intäkter uppgick till 9 122 (0) KSEK och avser försäljning av COVID-19 testkapasitet till kunder främst inom sport genom samarbetspartnern...
icke
regulatorisk
”Det är mycket viktigt för Qlife att vi erhåller en betydande order från en mycket professionell kund direkt efter vår CE-märkning. Det visar på efterfrågan för testning med laboratoriekvalitet med...
icke
regulatorisk
Danska patentverket har beviljat Qlife patentnummer DK180348 B1 för sin detekteringsenhet för biomarkörer. Enheten för biomarkörsdetektering består av ett integrerat optiskt mikroelektromekaniskt...
icke
regulatorisk
Det aktuella CE-märkningen gäller för professionell användning av testplattformen Egoo.Health och för försäljning på den europeiska marknaden. Nästa steg är att placera COVID-19 testet på strategiska...
regulatorisk
Qlife förväntar CE-märkning för professionell användning av Bolagets COVID-19 test i Egoo.Health-systemet inom kort. Med CE-märkningen kan Qlife’s kostnadseffektiva, snabba och mobila PCR-test...
icke
regulatorisk
Sedan maj 2020 har Qlife hanterat alla tester för COVID-19 för professionell fotboll i Danmark. Testkapaciteten inkluderar veckovis testning av alla spelare och personal i ligaklubbar för att minska...
icke
regulatorisk
Den 13 november fick Qlife beskedet från Lægemiddelstyrelsen att bolagets ansökan om tillfälligt godkännande i Danmark ”i hälsoskyddets intresse” för bolagets COVID-19 test får preliminärt...
icke
regulatorisk
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high...
regulatorisk
Beslut om (A) personaloptionsprogram; och (B) riktad emission av teckningsoptioner samt godkännande av överlåtelse av teckningsoptioner
Stämman beslutade i enlighet med styrelsens förslag att...
regulatorisk
TREDJE KVARTALET 1 JULI - 30 SEPTEMBER 2020
Periodens intäkter uppgick till 5 062 (714) KSEK och avser försäljning av COVID-19 testkapasitet till kunder främst inom sport, genom samarbetspartnern...
regulatorisk
Parallellt med den pågående processen att förbereda och sammanställa dokumentationen för CE-godkännandet, har Qlife lämnat in en ansökan om att lansera produkten i Danmark, eftersom det innebär en...
icke
regulatorisk
Valberedningen består av följande personer, vilka tillsammans representerar cirka 39 procent av antalet aktier och röster i bolaget baserat på senast kända aktieägarinformation:
Sören Skjärbäk,...
regulatorisk
Information med anledning av coronaviruset
Som en försiktighetsåtgärd för att minska risken för spridning av coronaviruset har styrelsen i Qlife Holding AB (”Qlife”) beslutat att begränsa planerade...
regulatorisk
Qlife förväntade ett CE-godkännande för produkten under oktober, men bolaget förväntar nu godkännandet inom kommande två till tre månader. Parallellt har Qlife lämnat in en ansökan till danska...
icke
regulatorisk
Due to the increasing of infectious rates over the past few weeks, it has been agreed that Qlife will be handling all testing for COVID-19 for professional handball in Denmark. Testing will start...
regulatorisk
ANDRA KVARTALET 1 APRIL - 30 JUNI 2020
Periodens intäkter uppgick till 6 181 (0) KSEK och avser i huvudsak försäljning till KMD avseende avtal med Danska Fotbolls Ligan för att testa spelare och...
icke
regulatorisk
In cooperation with KMD, Qlife has extended the contract with Divisionsforeningen. The extended contract is the continuation of COVID-19 testing of players and personnel in the two best football...
icke
regulatorisk
Qlife's focus on professional sports is centered around COVID-19 testing, which the company offers in collaboration with IT partner KMD. COVID-19 testing contracts have been closed with various...
icke
regulatorisk
In April we closed a contract with the professional Danish football league for regular testing of all players and staff for COVID-19 and delivery of test results were initiated already in week 22....
regulatorisk
“Henrik Ljung tillför Qlife bred erfarenhet från såväl finansiell rapportering, IR, affärskontroll, finansledning som bolagsstyrning, allt med fokus på snabbväxande bolag i tidig fas. Det är med stor...
icke
regulatorisk
KMD and Qlife has entered an agreement with Badminton Denmark to COVID-19 test all players in the final game of the Danish badminton tournament for clubs, RSL Final 4.
"The fact that we COVID-19...
icke
regulatorisk
Geelmuyden Kiese and KMD announced earlier today that they have entered a partnership to provide smart and efficient Covid-19 test solutions for the professional sports, culture, and entertainment...
icke
regulatorisk
The first phase of developing the antibody test will be outsourced to an existing partner and is expected to take approximately three months. Thereafter, the project will be transferred to in-house...
icke
regulatorisk
Qlife announced on 22 April that a research agreement had been made with Nordsjällands Hospital (NOH), for continued validation of the COVID-19 test. The validation at NOH was initiated immediately...
regulatorisk
Beslut om fastställande av räkenskaper samt resultatdisposition
Årsstämman beslutade att fastställa resultat- och balansräkning samt koncernresultat- och koncernbalansräkning. Årsstämman beslutade...
regulatorisk
FINANSIELL SAMMANFATTNING FÖRSTA KVARTALET 2020
Periodens intäkter uppgick till 385 (0) KSEK och avser ett samarbetsprojekt med ett danskt sjukhus.
EBITDA för perioden uppgick till -5 732 (-1 875...
regulatorisk
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga). The parties have developed a test protocol...
icke
regulatorisk
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test. The focus of the collaboration is to...
regulatorisk
Information med anledning av coronaviruset
Som en försiktighetsåtgärd för att minska risken för spridning av coronaviruset har styrelsen i Qlife Holding AB (”Qlife”) beslutat att begränsa planerade...
icke
regulatorisk
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following: After having finalized the licensing agreement to COVID-19...
regulatorisk
Molekylär (DNA/RNA) virustestning var påtänkt att utvecklas för Egoo-plattformen i ett senare skede. Tack vare den senaste tidens positiva teknikintegration och den starkt ökade efterfrågan på...
icke
regulatorisk
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak. The interest...
icke
regulatorisk
Qlife Holding AB meddelar att handel i bolagets aktier (kortnamn QLIFE) och teckningsoptioner serie TO1 (QLIFE TO1) inleds idag på Nasdaq First North Growth Market i Stockholm. Qlife Holding AB (“...
icke
regulatorisk
Aktiens kortnamn är QLIFE. Teckningsoptionerna av serie TO1 handlas under kortnamn QLIFE TO1.
Qlife har anlitad G&W Fondkommission som certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@...
icke
regulatorisk
Qlife har genomfört en emission i Bolaget genom att inför den planerade listningen på Nasdaq First North Growth Market erbjuda allmänheten och institutionella investerare i Sverige och utomlands att...
icke
regulatorisk
Egoo Home System är en integrerad plattform som består av ett litet mätinstrument med tillhörande engångskapslar och mjukvara, där varje kapsel innehåller ett test för en specifik biomarkör. Den...
regulatorisk
Qlife är ett svenskt moderbolag till det helägda danska medicintekniska dotterbolaget Qlife ApS. Qlife ApS utvecklar en innovativ medicinteknisk produkt med det långsiktiga målet att ge människor...
icke
regulatorisk
VD Thomas Warthoe kommer att presentera Qlife på Stora Aktiedagen i Stockholm den 25/11. Vill ni läsa mer om dagarnas hela program och anmälan, se bifogad anmälan.
icke
regulatorisk
VD Thomas Warthoe kommer att presentera Qlife på Stora Aktiedagen i Göteborg den 4/11 och Stockholm den 25/11. Vill ni läsa mer om dagarnas hela program och anmälan, se bifogad anmälan.
icke
regulatorisk
The home diagnostic device from Danish start-up Qlife can make the lives of patients with chronic diseases easier. This is the way forward towards a more human centered public health sector, says one...
icke
regulatorisk
Qlife præsenteres af den danske sundhedsminister og erhvervsminister under lancering af nyt offentlig program som fremmer partnerskaber for innovationsfremmende sundhedsudbud for medicinsk udstyr...
icke
regulatorisk
I bifogade nyhetsbrev (enbart på engelska) får du uppdatering om vår verksamhet och våra förberedelser inför nästa steg.
icke
regulatorisk
Totalt sex intressanta bolag presenterar sin verksamhet.
Se filmen från presentationen
icke
regulatorisk
Det danska sjukvårdssystemet producerar stora mängder data varje dag. I framtiden kommer nya datakällor såsom data från patienter och inte minst personliga hälsoinstrument och appar att få mängden...
icke
regulatorisk
Biologiska markörer i vårt blod kan visa mycket om vår hälsa, utvecklingen av en sjukdom eller eller hur hårt vi har drivit på kroppen under ett träningspass. Men det har hittills krävt tillgång till...